Obesity pharmacotherapy review names CagriSema among emerging combinations, reports no trial data
A narrative review in the Indian Journal of Pharmacology surveys approved obesity drugs and lists CagriSema among emerging dual and triple combinations. The abstract reports no new patient data and no dosing.
Indian journal of pharmacology · 2026 · Review · Other species · Published October 12, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the review did
This source is a narrative review article rather than a study in human participants, animals, or cells, so no species is enrolled and no sample size is reported. The abstract describes the current landscape of pharmacological management of obesity and the agents the authors describe as the emerging pipeline.
The authors frame obesity as "a chronic, multifactorial, and progressive disease as opposed to mere excess of body weight," and state that it increases the risk of type 2 diabetes, cardiovascular disease, metabolic-associated fatty liver disease, and mental health disorders.
What it reported
The abstract states that 2022 data show nearly 3 billion individuals worldwide were living with either obesity or overweight. It notes that earlier medications acting on the brain's monoaminergic pathways were withdrawn over safety concerns.
The authors list six medications currently approved by the U.S. Food and Drug Administration for long-term obesity management: Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, and Tirzepatide. CagriSema appears only in a forward-looking sentence, grouped with Survodutide and Retatrutide as new dual and triple combinations the authors describe as part of a promising pipeline, alongside long-acting and oral formulations.
The abstract also records that India released a new obesity guideline in January 2025 emphasizing early pharmacotherapy initiation and stage-based obesity classification.
Limitations
This is a review, not an original study. The abstract reports no participants, no comparison groups, no effect sizes, no adverse-event rates, and no statistical results for any named drug, including CagriSema. Claims about efficacy are stated by the authors in general terms rather than supported with numbers inside the abstract.
The abstract does not report any dosing regimen for cagrilintide, CagriSema, or any other agent it names, so no regimen can be described here. Selection of included literature, search methods, funding, and author affiliations are not stated in the abstract excerpt, and the comparison the authors draw to bariatric surgery is presented without supporting data in the text available.
Regulatory context
Cagrilintide, the amylin analogue coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use, according to the site's own regulatory review. The abstract itself lists CagriSema only among emerging pipeline agents, not among the six FDA-approved long-term obesity medications it names.
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The review lists CagriSema among emerging dual and triple combination therapies for obesity.
“It has new dual and triple combinations such as CagriSema, Survodutide, and Retatrutide for better efficacy and metabolic outcomes”
The authors name six medications as FDA-approved for long-term obesity management, a list that does not include CagriSema.
“Currently, six medications (Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, and Tirzepatide) are approved by the U.S. Food and Drug Administration for long-term obesity management”
The abstract cites 2022 data on the global number of people with obesity or overweight.
“2022 data reveal that nearly 3 billion individuals worldwide were living with either obesity or overweight.”
The authors state that earlier monoaminergic obesity drugs were withdrawn for safety reasons.
“Earlier medications targeted primarily the brain's monoaminergic pathways but they were withdrawn due to safety concerns.”
The review notes a January 2025 Indian obesity guideline emphasizing early pharmacotherapy and stage-based classification.
“India released its new obesity guideline in January 2025, emphasizing on early pharmacotherapy initiation and the adoption of stage-based obesity classification.”
Common questions
Does this abstract report any dosing for CagriSema or cagrilintide?
No. The abstract does not report a regimen, dose, frequency, or route for CagriSema or any other agent it names.
Did this source test CagriSema in patients?
No. It is a review article. The abstract reports no participants, no comparison group, and no outcome data for any individual drug.
What does the abstract actually say about CagriSema?
It appears in one sentence listing new dual and triple combinations, alongside Survodutide and Retatrutide, which the authors associate with better efficacy and metabolic outcomes in the emerging pipeline.
Is CagriSema described as FDA-approved in this abstract?
No. The abstract names Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, and Tirzepatide as the six FDA-approved long-term obesity medications, and places CagriSema in the pipeline instead.
Source
- 1.Pharmacological management of obesity: Current landscape and emerging therapies — Indian journal of pharmacology (2026)ReviewotherPMID 42683980DOI 10.4103/ijp.ijp_37_26